111 related articles for article (PubMed ID: 11549589)
1. Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack.
Zietz C; Rumpler U; Stürzl M; Löhrs U
Am J Pathol; 2001 Sep; 159(3):963-70. PubMed ID: 11549589
[TBL] [Abstract][Full Text] [Related]
2. Fas-related apoptosis in gastric adenocarcinoma.
Lim SC
Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
[TBL] [Abstract][Full Text] [Related]
3. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
4. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.
Okada K; Komuta K; Hashimoto S; Matsuzaki S; Kanematsu T; Koji T
Clin Cancer Res; 2000 Sep; 6(9):3560-4. PubMed ID: 10999744
[TBL] [Abstract][Full Text] [Related]
5. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
Michael-Robinson JM; Pandeya N; Cummings MC; Walsh MD; Young JP; Leggett BA; Purdie DM; Jass JR; Radford-Smith GL
J Pathol; 2003 Sep; 201(1):46-54. PubMed ID: 12950016
[TBL] [Abstract][Full Text] [Related]
7. The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability.
Houston AM; Michael-Robinson JM; Walsh MD; Cummings MC; Ryan AE; Lincoln D; Pandeya N; Jass JR; Radford-Smith GL; O'Connell J
Hum Pathol; 2008 Feb; 39(2):243-50. PubMed ID: 17961631
[TBL] [Abstract][Full Text] [Related]
8. FAS and FAS-L expression by tumor cells and lymphocytes in breast carcinomas and their lymph node metastases.
Ioachim HL; Decuseara R; Giancotti F; Dorsett BH
Pathol Res Pract; 2005; 200(11-12):743-51. PubMed ID: 15792116
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.
Shimonishi T; Isse K; Shibata F; Aburatani I; Tsuneyama K; Sabit H; Harada K; Miyazaki K; Nakanuma Y
Hepatology; 2000 Oct; 32(4 Pt 1):761-9. PubMed ID: 11003620
[TBL] [Abstract][Full Text] [Related]
10. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
Koyama S; Koike N; Adachi S
J Cancer Res Clin Oncol; 2002 Feb; 128(2):73-9. PubMed ID: 11862476
[TBL] [Abstract][Full Text] [Related]
11. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
Shukuwa T; Katayama I; Koji T
Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis and Fas-ligand expression correlate to the histopathological grade of gastric smooth muscle tumors.
Liu Y; Chen C; Chen C; Hsieh H; Chang C; Shyu J; Yen C; Harn H
J Surg Res; 2001 Feb; 95(2):92-8. PubMed ID: 11162031
[TBL] [Abstract][Full Text] [Related]
13. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D
Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065
[TBL] [Abstract][Full Text] [Related]
14. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
[TBL] [Abstract][Full Text] [Related]
15. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract][Full Text] [Related]
16. Elevated Fas expression is related to increased apoptosis of circulating CD8+ T cell in patients with gastric cancer.
Yoshikawa T; Saito H; Osaki T; Matsumoto S; Tsujitani S; Ikeguchi M
J Surg Res; 2008 Aug; 148(2):143-51. PubMed ID: 18561948
[TBL] [Abstract][Full Text] [Related]
17. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
18. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
Xue C; Lan-Lan W; Bei C; Jie C; Wei-Hua F
Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
[TBL] [Abstract][Full Text] [Related]
19. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
Elnemr A; Ohta T; Yachie A; Kayahara M; Kitagawa H; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
Int J Oncol; 2001 Jan; 18(1):33-9. PubMed ID: 11115536
[TBL] [Abstract][Full Text] [Related]
20. Fas/Fas ligand system and apoptosis induction in testicular carcinoma.
Schmelz HU; Abend M; Kraft K; Hauck EW; Weidner W; Van Beuningen D; Sparwasser C
Cancer; 2002 Jul; 95(1):73-81. PubMed ID: 12115319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
